Newswires
Efficacy of Alpha-blockers (Tamsulosin) in the Treatment of Symptomatic Dysuria in Multiple Sclerosis in Women: Cardiovascular Diseases and Conditions – Orthostatic Hypotension
Insurance Daily News
2022 JUL 14 (NewsRx) -- By a
As a matter of record, on
Tracking Information
| Trial Identifier | NCT05439902 |
| First Submitted Date | |
| First Posted Date | |
| Results First Submitted Date | Not Provided |
| Results First Posted Date | Not Provided |
| Last Update Submitted Date | |
| Last Update Posted Date | |
| Primary Completion Date | |
| Start Date | |
| Current Primary Outcome Measures | •Urinary symptoms between groups [ Time Frame: Start of first intervention phase (Day 0) ] -- Measured using the International Prostate Symptom Scale (IPSS), scoring ranging from 0-35 |
| •Urinary symptoms between groups [ Time Frame: End of first intervention phase (Day 30) ] -- Measured using the International Prostate Symptom Scale (IPSS), scoring ranging from 0-35 | |
| •Urinary symptoms between groups [ Time Frame: Start of first intervention phase (Day 60) ] -- Measured using the International Prostate Symptom Scale (IPSS), scoring ranging from 0-35 | |
| •Urinary symptoms between groups [ Time Frame: End of first intervention phase (Day 90) ] -- Measured using the International Prostate Symptom Scale (IPSS), scoring ranging from 0-35 | |
| Current Secondary Outcome Measures | •Urinary symptoms between groups [ Time Frame: Start of first intervention phase (Day 0) ] -- Measured using the Urinary Symptom Profile (USP) questionnaire: score ranging from 0-39 |
| •Urinary symptoms between groups [ Time Frame: End of first intervention phase (Day 30) ] -- Measured using the Urinary Symptom Profile (USP) questionnaire: score ranging from 0-39 | |
| •Urinary symptoms between groups [ Time Frame: Start of first intervention phase (Day 60) ] -- Measured using the Urinary Symptom Profile (USP) questionnaire: score ranging from 0-39 | |
| •Urinary symptoms between groups [ Time Frame: End of first intervention phase (Day 90) ] -- Measured using the Urinary Symptom Profile (USP) questionnaire: score ranging from 0-39 | |
| •Post-mictional residue between groups [ Time Frame: Start of first intervention phase (Day 0) ] -- ml, measured with BladderScan | |
| •Post-mictional residue between groups [ Time Frame: End of first intervention phase (Day 30) ] -- ml, measured with BladderScan | |
| •Post-mictional residue between groups [ Time Frame: Start of first intervention phase (Day 60) ] -- ml, measured with BladderScan | |
| •Post-mictional residue between groups [ Time Frame: End of first intervention phase (Day 90) ] -- ml, measured with BladderScan | |
| •Maximum urine flow rate between groups [ Time Frame: Start of first intervention phase (Day 0) ] -- ml/s | |
| •Maximum urine flow rate between groups [ Time Frame: End of first intervention phase (Day 30) ] -- ml/s | |
| •Maximum urine flow rate between groups [ Time Frame: Start of first intervention phase (Day 60) ] -- ml/s | |
| •Maximum urine flow rate between groups [ Time Frame: End of first intervention phase (Day 90) ] -- ml/s | |
| •Quality of life linked to urinary dysfunction between groups [ Time Frame: Start of first intervention phase (Day 0) ] -- Qualiveen-30 questionnaire; score 0-4 | |
| •Quality of life linked to urinary dysfunction between groups [ Time Frame: End of first intervention phase (Day 30) ] -- Qualiveen-30 questionnaire; score 0-4 | |
| •Quality of life linked to urinary dysfunction between groups [ Time Frame: Start of first intervention phase (Day 60) ] -- Qualiveen-30 questionnaire; score 0-4 | |
| •Quality of life linked to urinary dysfunction between groups [ Time Frame: End of first intervention phase (Day 90) ] -- Qualiveen-30 questionnaire; score 0-4 | |
| •Quality of life between groups [ Time Frame: Start of first intervention phase (Day 0) ] -- EQ-5D questionnaire; score 0-100 | |
| •Quality of life between groups [ Time Frame: End of first intervention phase (Day 30) ] -- EQ-5D questionnaire; score 0-100 | |
| •Quality of life between groups [ Time Frame: Start of first intervention phase (Day 60) ] -- EQ-5D questionnaire; score 0-100 | |
| •Quality of life between groups [ Time Frame: End of first intervention phase (Day 90) ] -- EQ-5D questionnaire; score 0-100 | |
| •Fatigue between groups [ Time Frame: Start of first intervention phase (Day 0) ] -- Modified Fatigue Impact Scale; score 0-84 | |
| •Fatigue between groups [ Time Frame: End of first intervention phase (Day 30) ] -- Modified Fatigue Impact Scale; score 0-84 | |
| •Fatigue between groups [ Time Frame: Start of first intervention phase (Day 60) ] -- Modified Fatigue Impact Scale; score 0-84 | |
| •Fatigue between groups [ Time Frame: End of first intervention phase (Day 90) ] -- Modified Fatigue Impact Scale; score 0-84 | |
| •Drug safety [ Time Frame: End of first intervention phase (Day 30) ] -- Yes/no occurence of the following adverse events: headache, asthenia, gastrointestinal disorders, orthostatic hypotension | |
| •Drug safety [ Time Frame: End of first intervention phase (Day 90) ] -- Yes/no occurence of the following adverse events: headache, asthenia, gastrointestinal disorders, orthostatic hypotension | |
| Other Outcome Measures | Not Provided |
| Change History | Complete list of historical revisions of study NCT05439902 |
Descriptive Information
| Brief Title | Efficacy of Alpha-blockers (Tamsulosin) in the Treatment of Symptomatic Dysuria in Multiple Sclerosis in Women |
| Official Title | Efficacy of Alpha-blockers (Tamsulosin) in the Treatment of Symptomatic Dysuria in Multiple Sclerosis in Women |
| Brief Summary | Multiple sclerosis (MS) is the leading non-traumatic cause of severe acquired disability in young people. The disease is defined by relapses, which can affect all neurological functions depending on the location of the new inflammatory lesion(s). The disease can thus manifest itself through bladder and bowel disorders (BWS), which affect approximately 80% of MS patients in all stages. Lower urinary tract dysfunction has a significant negative impact on the quality of life of patients and places a significant burden on the healthcare system in terms of resource allocation. In addition, there is a risk of long-term chronic renal failure, an infectious risk (recurrent cystitis and/or pyelonephritis, sometimes life-threatening) and a lithiasis risk. The most frequently observed urinary symptoms are: urinary frequency, urgency with or without urinary incontinence, dysuria and chronic retention of urine. These disorders most often combine bladder hyperactivity and dysuria. This dysuria may be responsible for recurrent urinary tract infections, lithiasis, alteration of renal function. The only therapeutic class currently used to treat dysuria in MS is alpha-blockers. Tamsulosin, alfusozin and doxazosin induce relaxation of the urethral smooth sphincter and prostatic urethral muscle fibers, facilitating the removal of subvesical obstruction and bladder emptying. The study investigators hypothesize that treatment with tamsulosin 0.4 mg daily in adult MS patients with dysuria will result in symptom improvement as assessed by the International Prostate Symptom Score (IPSS) and Urinary Symptom Profile (USP) scores, a decrease in post-void residual, and an improvement in urine flow and quality of life. |
| Detailed Description | Not Provided |
| Study Type | Interventional |
| Study Phase | Not Applicable |
| Study Design | Allocation: Randomized |
| Intervention Model: Crossover Assignment | |
| Primary Purpose: Treatment | |
| Masking: Triple | |
| Intervention Model Description: One month of intervention of drug or placebo followed by one month wash-out period and then final one month intervention with the remaining treatment not received in the first cycle. | |
| Condition | Multiple Sclerosis |
| Dysuria | |
| Lower Urinary Tract Symptoms | |
| Voiding Dysfunction | |
| Urinary Retention | |
| Intervention | •Drug: Tamsulosin |
| One 0.4mg Tamsulosin capsule taken per day for 30 days | |
| •Drug: Placebo | |
| one placebo capsule per day for 30 days. with identical appearance (color and size) to the experimental drug, composed of microcrystalline cellulose | |
| Study Arms | •Placebo Comparator: Placebo |
| Interventions: | |
| ⚬Drug: Placebo | |
| •Experimental: Tamsulosin | |
| Interventions: | |
| ⚬Drug: Tamsulosin |
Recruitment Information
| Recruitment Status | Not yet recruiting |
| Estimated Enrollment | 60 |
| Estimated Completion Date | |
| Primary Completion Date | |
| Eligibility | Inclusion Criteria: The patient must have given their free and informed consent and signed the consent form The patient must be a member or beneficiary of a health insurance plan Patient with multiple sclerosis (EDSS score < 7.5). Moderate to severe dysuria (IPSS score > 7) due to bladder sphincter dyssynergia confirmed by complete urodynamic workup. Patient under stable treatment. Exclusion Criteria: The subject is participating in another category 1 interventional study, or a trial involving a non-CE marked or CE marked off-label medical device or is in a period of exclusion determined by a previous study The subject refuses to sign the consent It is impossible to give the subject informed information The patient is under safeguard of justice or state guardianship Hypersensitivity to tamsulosin hydrochloride, including angioedema induced by the drug or any of the excipients. History of orthostatic hypotension. Severe hepatic impairment. Concomitant treatment with diclofenac, warfarin, CYP3A4 inhibitors. |
| •Patient with complete urinary retention at the time of the pre-inclusion consultation, requiring management by intermittent self-catheterization or, failing that, an indwelling bladder catheter from the outset. Major medical or psychiatric illness that, in the opinion of the investigator, would place the subject at risk or could compromise compliance with the study protocol. Presence of another neurological pathology (excluding MS). Swallowing problems that compromise oral medication. Scheduled cataract surgery within 4 months. Pregnant, parturient or breastfeeding patient. | |
| Sex/Gender | Sexes Eligible for Study: Female |
| Ages | 18 years and older |
| No | |
| Contacts | Primary contact: |
| Listed Location Countries | |
| Removed Location Countries |
Administrative Information
| NCT Number | NCT05439902 |
| Other Study ID Numbers | NIMAO/2021-1/EB-01 |
| Has Data Monitoring Committee | Not Provided |
| Not Provided | |
| Plan to Share Data | Not Provided |
| Plan to Share Data (IPD) Description | Not Provided |
| Collaborators | Not Provided |
| Investigators | Principal Investigator: |
| Information Provided By | |
| Verification Date |
(Our reports deliver fact-based news of research and discoveries from around the world.)
Patent Issued for System for automated resource set multi-factor risk analysis (USPTO 11373129): Hartford Fire Insurance Company
Patent Issued for Systems and methods for detecting digital security breaches of connected assets based on location tracking and asset profiling (USPTO 11373245): Allstate Insurance Company
Advisor News
- Nationwide Financial Services President John Carter to retire at year end
- FINRA, FBI warn about generative AI and finances
- Prudential study: Babies born today will likely need nearly $2M to retire
- Economy performing better than expected, Morningstar says
- Advisors have more optimism post-election
More Advisor NewsAnnuity News
- Prudential Financial to Reinsure $7B Japanese Whole Life Block with Prismic Life
- Nationwide Financial Services President John Carter to retire at year end
- Pension Rights Center: PRT deals could lead to ‘nationwide catastrophe’ regulated
- Allianz Life Retirement Solutions Now Available Through Morgan Stanley
- Midland Advisory Focused on Growing Registered Investment Advisor Channel Presence
More Annuity NewsHealth/Employee Benefits News
- Insider named as new CEO for UnitedHealthcare insurance business
- FastTrack and RGA Partner to Bring Digital Workflow Automation and Claims System Technology to RGA Clients
- Stock market today: Wall Street mixed in premarket as airlines drag and insurance companies rise
- Voya launches innovative new permanent life insurance offering through the workplace
- Council Reviews Health Care Options at Special Meeting
More Health/Employee Benefits NewsLife Insurance News
- Prudential Financial and Dai-ichi Life to Pursue Strategic Partnership
- AM Best Removes From Under Review With Positive Implications and Upgrades Credit Ratings of ShelterPoint Insurance Company and ShelterPoint Life Insurance Company
- Prudential inks $7 billion reinsurance deal with Bermuda-based reinsurer
- Securian Financial Announces Chief Financial Officer Transition
- Voya launches innovative new permanent life insurance offering through the workplace
More Life Insurance News